<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: negative cash flow as", fill: "#ad6f69"},
{source: "2: negative cash flow as", target: "2: manufacturing marketing", fill: "#ad6f69"},
{source: "2: manufacturing marketing", target: "2: sales capabilities research", fill: "#ad6f69"},
{source: "2: sales capabilities research", target: "2: product development", fill: "#ad6f69"},
{source: "2: product development", target: "2: administrative costs", fill: "#ad6f69"},
{source: "2: negative cash flow as", target: "4: become profitable", fill: "#20b2aa"},
{source: "4: become profitable", target: "4: future will depend on among", fill: "#20b2aa"},
{source: "4: future will depend on among", target: "4: distribution", fill: "#20b2aa"},
{source: "4: distribution", target: "4: increase sales", fill: "#20b2aa"},
{source: "4: increase sales", target: "4: introduce new products into", fill: "#20b2aa"},
{source: "4: introduce new products into", target: "4: marketing sales", fill: "#20b2aa"},
{source: "4: marketing sales", target: "4: continue existing collaborations", fill: "#20b2aa"},
{source: "4: continue existing collaborations", target: "4: establish successful new collaborations", fill: "#20b2aa"},
{source: "4: establish successful new collaborations", target: "4: with corporate partners", fill: "#20b2aa"},
{source: "4: with corporate partners", target: "4: market products", fill: "#20b2aa"},
{source: "4: market products", target: "4: incorporate", fill: "#20b2aa"},
{source: "4: incorporate", target: "4: technologies", fill: "#20b2aa"},
{source: "4: technologies", target: "4: provide necessary funding", fill: "#20b2aa"},
{source: "4: become profitable", target: "5: early stage", fill: "#967117"},
{source: "5: early stage", target: "5: development", fill: "#967117"},
{source: "5: development", target: "5: diagnostics", fill: "#967117"},
{source: "5: diagnostics", target: "5: products into", fill: "#967117"},
{source: "5: early stage", target: "8: possibilities", fill: "#f3c"},
{source: "8: possibilities", target: "8: approach may", fill: "#f3c"},
{source: "8: approach may", target: "8: compatible with existing technology", fill: "#f3c"},
{source: "8: compatible with existing technology", target: "8: technology", fill: "#f3c"},
{source: "8: technology", target: "8: may rely on", fill: "#f3c"},
{source: "8: may rely on", target: "8: become obsolete", fill: "#f3c"},
{source: "8: become obsolete", target: "8: found ineffective", fill: "#f3c"},
{source: "8: found ineffective", target: "8: regulatory standards", fill: "#f3c"},
{source: "8: regulatory standards", target: "8: necessary regulatory clearances", fill: "#f3c"},
{source: "8: necessary regulatory clearances", target: "8: market size", fill: "#f3c"},
{source: "8: market size", target: "8: products may prove", fill: "#f3c"},
{source: "8: products may prove", target: "8: third parties may market", fill: "#f3c"},
{source: "8: third parties may market", target: "8: equivalent products", fill: "#f3c"},
{source: "8: equivalent products", target: "8: market due", fill: "#f3c"},
{source: "8: market due", target: "8: associated with", fill: "#f3c"},
{source: "8: possibilities", target: "14: impairment", fill: "#ff003f"},
{source: "14: impairment", target: "14: operations", fill: "#ff003f"},
{source: "14: impairment", target: "22: enter into collaborative relationships with", fill: "#a3c1ad"},
{source: "22: enter into collaborative relationships with", target: "22: established healthcare", fill: "#a3c1ad"},
{source: "22: established healthcare", target: "22: assist us", fill: "#a3c1ad"},
{source: "22: assist us", target: "22: technologies", fill: "#a3c1ad"},
{source: "22: technologies", target: "22: manufacturing", fill: "#a3c1ad"},
{source: "22: manufacturing", target: "22: certain markets", fill: "#a3c1ad"},
{source: "22: enter into collaborative relationships with", target: "33: raise necessary", fill: "#c72c48"},
{source: "33: raise necessary", target: "33: additional capital by issuing additional debt", fill: "#c72c48"},
{source: "33: additional capital by issuing additional debt", target: "33: equity securities", fill: "#c72c48"},
{source: "33: raise necessary", target: "35: raise additional capital", fill: "#9bddff"},
{source: "35: raise additional capital", target: "35: by selling additional common", fill: "#9bddff"},
{source: "35: by selling additional common", target: "35: preferred stock", fill: "#9bddff"},
{source: "35: preferred stock", target: "35: stockholders would", fill: "#9bddff"},
{source: "35: raise additional capital", target: "57: consolidation", fill: "#faf0be"},
{source: "57: consolidation", target: "57: pharmaceutical", fill: "#faf0be"},
{source: "57: pharmaceutical", target: "57: biotechnology industries could", fill: "#faf0be"},
{source: "57: biotechnology industries could", target: "57: potential customers", fill: "#faf0be"},
{source: "57: potential customers", target: "57: competing products", fill: "#faf0be"},
{source: "57: competing products", target: "57: inhouse capabilities", fill: "#faf0be"},
{source: "57: consolidation", target: "163: biosecurity", fill: "#674846"},
{source: "163: biosecurity", target: "163: also highly sensitive", fill: "#674846"},
{source: "163: also highly sensitive", target: "163: international government policies", fill: "#674846"},
{source: "163: international government policies", target: "163: funding priorities", fill: "#674846"},
{source: "163: biosecurity", target: "164: government", fill: "#d1e231"},
{source: "164: government", target: "164: reductions", fill: "#d1e231"},
{source: "164: reductions", target: "164: materially", fill: "#d1e231"},
{source: "164: materially", target: "164: adversely", fill: "#d1e231"},
{source: "164: adversely", target: "164: government contracts", fill: "#d1e231"},
{source: "164: government contracts", target: "164: prospects could suffer", fill: "#d1e231"},
{source: "164: government", target: "233: executive officers", fill: "#ff0090"},
{source: "233: executive officers", target: "233: directors", fill: "#ff0090"},
{source: "233: directors", target: "233: approximately", fill: "#ff0090"},
{source: "233: approximately", target: "233: outstanding shares", fill: "#ff0090"},
{source: "233: outstanding shares", target: "233: common stock", fill: "#ff0090"},
{source: "233: executive officers", target: "START_HERE", fill: "#ff0090"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_management">Technology management</a></td>
      <td>Technology management is a set of management disciplines that allows organizations to manage their technological fundamentals to create customer advantage. Typical concepts used in technology management are:\n\nTechnology strategy (a logic or role of technology in organization),\nTechnology forecasting (identification of possible relevant technologies for the organization, possibly through technology scouting),\nTechnology roadmap (mapping technologies to business and market needs), and\nTechnology project portfolio (a set of projects under development) and technology portfolio (a set of technologies in use).The role of the technology management function in an organization is to understand the value of certain technology for the organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government">Government</a></td>
      <td>A government is the system or group of people governing an organized community, generally a state.\nIn the case of its broad associative definition, government normally consists of legislature, executive, and judiciary.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Australian_Government">Australian Government</a></td>
      <td>The Australian Government, also known as the Commonwealth Government, is the national government of Australia, a federal parliamentary constitutional monarchy. Like other Westminster-style systems of government, the Australian Government is made up of three branches: the executive (the prime minister, the ministers, and government departments), the legislative (the Parliament of Australia), and the judicial.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_agency">Government agency</a></td>
      <td>A government or state agency, sometimes an appointed commission, is a permanent or semi-permanent organization in the machinery of government that is responsible for the oversight and administration of specific functions, such as an administration. There is a notable variety of agency types.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Executive_(government)">Executive (government)</a></td>
      <td>The executive (short for executive branch or executive power) is the part of government that enforces law, and has responsibility for the governance of a state.\nIn political systems based on the principle of separation of powers, authority is distributed among several branches (executive, legislative, judicial)—an attempt to prevent the concentration of power in the hands of a single group of people.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_of_Canada">Government of Canada</a></td>
      <td>The government of Canada (French: gouvernement du Canada) is the body responsible for the federal administration of Canada. A constitutional monarchy, the Crown is the corporation sole, assuming distinct roles: the executive, as the Crown-in-Council; the legislature, as the Crown-in-Parliament; and the courts, as the Crown-on-the-Bench.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Islamic_government">Islamic government</a></td>
      <td>Velayat-e faqih (Persian: ولایت فقیه, velāyat-e faqīh), also known as Islamic Government (Persian: حکومت اسلامی, Hokumat-i Eslami), is a book by the Iranian Muslim cleric, faqīh, and revolutionary Ayatollah Ruhollah Khomeini, first published in 1970, and the most influential document written in modern times in support of theocratic rule.\nThe book argues that government should be run in accordance with traditional Islamic  law (sharia), and for this to happen a leading Islamic jurist (faqih) must provide political "guardianship" (wilayat or velayat) over the people and nation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>BIOVERIS CORP      Item 1A <font color="blue">Risk Factors       </font>25       ITEM 1A RISK FACTORS         Forward-Looking Information and Risk Factors That May Affect Future Results         Risks Relating to Us and Our Business         OUR BUSINESS HAS A HISTORY OF LOSSES AND WE EXPECT TO HAVE FUTURE LOSSES AND     NEGATIVE CASH FLOW         We <font color="blue">incurred net losses</font> of dlra27dtta9 million, dlra77dtta6 million and dlra93dtta3 million for     the years ended March 31, 2006, 2005 and 2004, respectively</td>
    </tr>
    <tr>
      <td>We expect to     continue to incur operating losses and <font color="blue">negative cash flow as</font> a result of our     expenses for <font color="blue">manufacturing</font>, marketing and sales capabilities, research and     <font color="blue">product <font color="blue">development</font></font>, and general and <font color="blue">administrative costs</font></td>
    </tr>
    <tr>
      <td>While we seek to attain profitability, we cannot be sure that we will ever     achieve product or other <font color="blue">revenue sufficient</font> for us to attain this objective</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">become profitable</font> in the future will depend on, among other     things, our ability to:         •       expand the <font color="blue">distribution</font> and <font color="blue">increase sales</font> of certain of our products;         •       upgrade and enhance the M-SERIES family of products;         •       <font color="blue">introduce new <font color="blue">products into</font></font> the market;         •       develop our marketing, sales and <font color="blue">distribution</font> capabilities cost-<font color="blue">effective</font>ly;     and         •       <font color="blue">continue existing <font color="blue"><font color="blue">collaboration</font>s</font></font> and <font color="blue">establish successful new <font color="blue"><font color="blue">collaboration</font>s</font></font>     <font color="blue">with corporate partners</font> to develop and <font color="blue">market products</font> that <font color="blue">incorporate</font> our     <font color="blue">technologies</font> and <font color="blue">provide <font color="blue">necessary</font> funding</font></td>
    </tr>
    <tr>
      <td>TO ACHIEVE COMMERCIAL SUCCESS, WE MUST COMPLETE THE DEVELOPMENT OF OUR     PRODUCTS AND THOSE PRODUCTS MUST GAIN MARKET ACCEPTANCE OR OUR BUSINESS     COULD BE MATERIALLY ADVERSELY AFFECTED         25       ______________________________________________________________________           Many of our potential products, including certain M-SERIES products, are at     an  <font color="blue">early stage</font> of <font color="blue">development</font> and we have not introduced any clinical     <font color="blue"><font color="blue">diagnostic</font>s</font>  <font color="blue">products into</font> the marketplace</td>
    </tr>
    <tr>
      <td>Products under <font color="blue">development</font>     require <font color="blue"><font color="blue">additional</font> research</font> and <font color="blue">development</font> efforts, including clinical     testing and <font color="blue"><font color="blue">regulatory</font> approval</font>, prior to <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>Our potential     products are subject to the risks of <font color="blue">failure inherent</font> in the <font color="blue">development</font> of     <font color="blue">products <font color="blue">based on</font> new</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>These risks include the <font color="blue">possibilities</font>     that:         •       our design or <font color="blue">approach may</font> not be successful;         •       our <font color="blue">products may</font> not be <font color="blue">compatible with existing <font color="blue">technology</font></font> or <font color="blue">may rely on</font>     <font color="blue">technology</font> that has <font color="blue">become obsolete</font>;         •       our <font color="blue">products may</font> be <font color="blue">found in<font color="blue">effective</font></font> or fail to meet the applicable     <font color="blue"><font color="blue">regulatory</font> standards</font> or receive <font color="blue"><font color="blue">necessary</font> <font color="blue">regulatory</font> clearances</font>;         •       our estimates of the <font color="blue">market size</font> and potential for our <font color="blue"><font color="blue">products may</font> prove</font>     incorrect;         •       <font color="blue"><font color="blue">third parties</font> may market</font> superior or <font color="blue">equivalent products</font>;         •       our <font color="blue">products may</font> not be recognized or accepted in the <font color="blue">market due</font> to     unfamiliar brand names; or         •       our <font color="blue">product <font color="blue">development</font></font> costs may outweigh potential future <font color="blue">cash flows</font>     <font color="blue">associated with</font> those products</td>
    </tr>
    <tr>
      <td>Our business, business prospects and financial results would be hurt if our     products are not <font color="blue">accepted as <font color="blue">alternative</font>s</font> to other existing or <font color="blue">new products</font>     and do not <font color="blue">gain market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>In addition, we have <font color="blue">licensed certain</font> PCR <font color="blue">technology</font> from Roche that we plan     to <font color="blue">integrate into certain</font> of our new instrument systems</td>
    </tr>
    <tr>
      <td>Although we do not     <font color="blue">currently sell</font> any <font color="blue">product <font color="blue">based on</font></font> the PCR <font color="blue">technology</font> licensed from Roche,     any products that we may develop using PCR <font color="blue">technology</font> will be also subject     to the risks of <font color="blue">failure inherent</font> in the <font color="blue">development</font> of <font color="blue">products <font color="blue">based on</font> new</font>     <font color="blue">technologies</font> as described above</td>
    </tr>
    <tr>
      <td>We have recorded a <font color="blue">net book value</font> for the PCR licenses of dlra15dtta4 million at     March 31, 2006</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> develop any <font color="blue">products using</font>     PCR <font color="blue">technology</font> because such PCR <font color="blue">technology</font> has <font color="blue">become obsolete</font> or the future     <font color="blue"><font color="blue">cash flows</font> attributable</font> to <font color="blue">products using</font> PCR <font color="blue">technology</font> are insufficient to     realize the remaining carrying value of the license, we would be required to     write-off the remaining <font color="blue">net book value</font> or record an <font color="blue">impairment</font> of the value     <font color="blue">of the PCR </font>license</td>
    </tr>
    <tr>
      <td>Such a write-off or the recording of such an <font color="blue">impairment</font>     could have a material adverse effect on our future results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>OUR QUARTERLY OPERATING RESULTS MAY FLUCTUATE SIGNIFICANTLY, AND THESE     FLUCTUATIONS MAY CAUSE OUR STOCK PRICE TO BE VOLATILE         Our quarterly operating results <font color="blue">will depend upon</font>:         •       the volume and timing of orders and <font color="blue">product deliveries</font> for <font color="blue">biosecurity</font>     products, M-SERIES systems or other products, which are <font color="blue">based on</font> our     customers’ <font color="blue">requirements</font> that <font color="blue">may vary over</font> time;         •       the success of M-SERIES <font color="blue">system upgrades</font> and <font color="blue">enhancements</font> and customer     <font color="blue">acceptance</font> of those <font color="blue">enhancements</font> and upgrades;         •       costs incurred related to <font color="blue">expansion into</font> the field of vaccines;         •       the amount of revenues recognized or <font color="blue">collectible from royalties</font> and other     contract revenues, which revenues are <font color="blue"><font color="blue">dependent</font> upon</font> the efforts and     compliance of our licensees and <font color="blue"><font color="blue">collaborator</font>s</font>, including Roche;         •       whether our <font color="blue">instruments</font> are sold or leased to customers, which will affect     the timing of the <font color="blue">recognition</font> of <font color="blue">revenue from</font> the sale or lease;         26       ______________________________________________________________________           •       the timing of our <font color="blue">introduction</font> of <font color="blue">new products</font>, <font color="blue">which could</font> involve     increased expenses <font color="blue">associated with</font> <font color="blue">product <font color="blue">development</font></font> and marketing;         •       the volume and timing of <font color="blue">product returns</font> and warranty claims, which, if     products are returned or have warranty claims that are unexpected, may     <font color="blue">involve increased costs</font> in excess of amounts reserved for returns or claims;         •       our <font color="blue">competitors</font>’ <font color="blue">introduction</font> of <font color="blue">new products</font>, which may affect the purchase     decision of or timing of <font color="blue">orders by</font> our customers and <font color="blue">prospective customers</font>     while the <font color="blue">competitors</font>’ product is assessed;         •       the amount of expenses we incur in <font color="blue"><font color="blue">connection</font> with</font> the operation of our     business, including:           •       research and <font color="blue">development</font> costs, which increase or decrease <font color="blue">based on</font> the     products in <font color="blue">development</font>; and           •       sales and marketing costs, which are <font color="blue">based on</font> product launches or promotions     and <font color="blue">sales incentives</font> that might be in effect from time to time;         •       the amount that we may record related to the potential <font color="blue">impairment</font> of the     license to use PCR <font color="blue">technology</font>;         •       amounts received from MSD or MST as payment for the purchase of our     interests in MSD and the related <font color="blue">accretion</font> of <font color="blue">income on</font> the note receivable     from MST;         •       <font color="blue">unexpected <font color="blue">termination</font></font> of <font color="blue"><font color="blue">government</font> contracts</font> or orders, <font color="blue">which could</font> result     in <font color="blue">decreased sales</font> and <font color="blue">increased costs due</font> to excess capacity, inventory,     personnel and other expenses; and         •       <font color="blue"><font color="blue">additional</font> costs which</font> we <font color="blue">may incur as</font> we <font color="blue">explore new healthcare</font>     <font color="blue">opportunities</font>, including costs for <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">technologies</font>, <font color="blue">facilities</font>     and personnel</td>
    </tr>
    <tr>
      <td>These  factors  may cause our quarterly operating results to fluctuate     <font color="blue">significant</font>ly, which in turn, may cause our stock price to be volatile</td>
    </tr>
    <tr>
      <td>In     addition, because our revenues and operating results are expected to be     volatile  and  <font color="blue">difficult</font>  to predict, we believe that period-to-period     <font color="blue">comparisons</font> of our results of <font color="blue">operations</font> are not a <font color="blue">reliable indication</font> of     our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>WE MAY CHANGE THE FOCUS OF OUR BUSINESS OR ENTER INTO NEW HEALTHCARE FIELDS,     WHICH COULD RESULT IN THE INCURRENCE OF ADDITIONAL COSTS AND EXPOSURE TO     ADDITIONAL OR DIFFERENT BUSINESS RISKS         We have <font color="blue">broad discretion</font> in determining the <font color="blue">future strategy</font> and focus of our     business and <font color="blue">may enter new healthcare fields</font> in which we have limited or no     experience</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> change in the focus of our business could     result in a loss of our <font color="blue">investment</font>, the incurrence of <font color="blue">additional</font> costs,     including research and <font color="blue">development</font> costs, and exposure to <font color="blue">additional</font> or     <font color="blue">different</font> business risks</td>
    </tr>
    <tr>
      <td><font color="blue">Incurrence </font>of <font color="blue">additional</font> costs and exposure to     <font color="blue">additional</font> risks could <font color="blue">materially</font> <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>IF WE ARE UNABLE TO ESTABLISH NEW COLLABORATIONS, OR IF ANY COLLABORATIONS     WE ESTABLISH DO NOT RESULT IN THE SUCCESSFUL INTRODUCTION OR MARKETING OF     NEW PRODUCTS BASED ON OUR TECHNOLOGY, OUR GROWTH MAY BE SLOWED AND OUR     BUSINESS COULD BE MATERIALLY ADVERSELY AFFECTED         One aspect of our strategy is to <font color="blue">enter into collaborative <font color="blue">relationships</font> with</font>     <font color="blue">established healthcare</font> and other companies to <font color="blue">assist us</font> in developing our     <font color="blue">technologies</font> or <font color="blue">manufacturing</font> or marketing our products for <font color="blue">certain markets</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">enter into <font color="blue"><font color="blue">collaboration</font>s</font> on terms</font> that are favorable     to  us,  if  at all</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">cannot assure</font> that <font color="blue">third parties</font>,     including our licensees, suppliers or <font color="blue">others will</font> not object to <font color="blue">possible new</font>     <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>As a result of this strategy, we may have no, or only limited, <font color="blue">control over</font>     the amount of resources that our         27       ______________________________________________________________________         <font color="blue"><font color="blue">collaborator</font>s</font> will devote to the <font color="blue">development</font> or marketing of <font color="blue">products based</font>     on our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>For instance, our <font color="blue"><font color="blue">collaborator</font>s</font>:         •       may decide not to, or may fail to <font color="blue">successfully</font>, develop, market or sell     products <font color="blue">based on</font> our <font color="blue">technology</font>;         •       may not <font color="blue">devote <font color="blue">sufficient resources</font></font> to the <font color="blue">development</font>, marketing or sale of     these products <font color="blue">based on</font> our <font color="blue">technology</font>; or,         •       <font color="blue">may terminate</font> their <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with us</font></td>
    </tr>
    <tr>
      <td>If any of these events occur <font color="blue">with respect</font> to one of the companies we are     <font color="blue">collaborating with</font>, we would not receive the benefits of the <font color="blue">collaboration</font>     and  our  growth  could be slowed and our business could be <font color="blue">materially</font>     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>WE MAY NOT BE ABLE TO RAISE SUFFICIENT ADDITIONAL CAPITAL TO SUCCESSFULLY     DEVELOP OUR BUSINESS         We will need substantial amounts of money to fund our <font color="blue">operations</font> on an     <font color="blue">ongoing basis</font></td>
    </tr>
    <tr>
      <td>We expect our available cash to be sufficient to fund our     <font color="blue">operations</font> for at least one year, but cannot predict how long our available     cash will be sufficient to fund our <font color="blue">operations</font> thereafter</td>
    </tr>
    <tr>
      <td>We may need to raise substantial amounts of money to fund a variety of     <font color="blue">future activities integral</font> to the <font color="blue">development</font> of our business, including:         •       for research and <font color="blue">development</font> to <font color="blue">successfully</font> develop our <font color="blue">technologies</font>,     including <font color="blue">future payment <font color="blue">obligations</font> under license</font> or <font color="blue">option <font color="blue"><font color="blue">agreement</font>s</font></font>;         •       to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for our products;         •       to file and <font color="blue">prosecute patent <font color="blue">application</font>s</font> to protect our <font color="blue">technology</font>;         •       to respond to <font color="blue">innovations</font> that our <font color="blue">competitors</font> develop;         •       to retain qualified employees, particularly in light of <font color="blue">competition</font> for     <font color="blue">qualified <font color="blue">scientists</font></font> and engineers;         •       to make <font color="blue">new arrangements</font> to market our <font color="blue">technology</font>;         •       to <font color="blue"><font color="blue">manufacture</font> products ourselves</font> or through a <font color="blue">third party</font>;         •       to <font color="blue">provide funding</font> for expanded or <font color="blue">new <font color="blue">facilities</font></font>; and         •       to market <font color="blue">different</font> products to <font color="blue">different</font> geographic markets, either through     expanding our sales and <font color="blue">distribution</font> capabilities or <font color="blue">relying on</font> a third     party</td>
    </tr>
    <tr>
      <td>The failure to raise sufficient <font color="blue">additional</font> capital for us to develop our     business would <font color="blue">adversely</font> affect our business prospects</td>
    </tr>
    <tr>
      <td>OUR ACCESS TO FUNDS COULD BE NEGATIVELY IMPACTED BY MANY FACTORS, INCLUDING     VOLATILITY IN THE PRICE OF OUR COMMON STOCK, LOSSES FROM OPERATIONS AND     CAPITAL MARKET CONDITIONS         We may not have access to <font color="blue">enough funds on</font> favorable terms, if at all, to     <font color="blue">successfully</font> operate and develop our business</td>
    </tr>
    <tr>
      <td>We may try to <font color="blue">raise <font color="blue">necessary</font></font>     <font color="blue">additional</font> capital by issuing <font color="blue">additional</font> debt or <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Holders     </font>of debt securities would have priority over our equity holders <font color="blue">with respect</font>     to the <font color="blue">proceeds from</font> the sale of our assets in the event of <font color="blue">liquidation</font> of     our business, and any <font color="blue">debt <font color="blue">financings</font></font> that we obtain <font color="blue">may contain restrictive</font>     terms that limit our operating <font color="blue">flexibility</font></td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> capital     by selling <font color="blue">additional</font> common or <font color="blue">preferred stock</font>, the holdings of existing     <font color="blue"><font color="blue">stockholders</font> would</font> be diluted</td>
    </tr>
    <tr>
      <td>28       ______________________________________________________________________           If  we are unable to raise <font color="blue">additional</font> capital, we may have to consider     <font color="blue">pursuing arrangements with</font> other companies that may not be <font color="blue">available on</font>     terms favorable to us</td>
    </tr>
    <tr>
      <td>WE MAY EXPERIENCE DESIGN, DEVELOPMENT, IMPLEMENTATION AND OTHER DIFFICULTIES     THAT       COULD DELAY OR PREVENT OUR INTRODUCTION OF NEW OR ENHANCED PRODUCTS OR     AFFECT THE PERFORMANCE OF EXISTING PRODUCTS, WHICH COULD ADVERSELY AFFECT     OUR BUSINESS IN ADDITION, IF THE MARKETS FOR OUR PRODUCTS CHANGE OR EVOLVE     IN  AN  UNEXPECTED  MANNER, OUR BUSINESS COULD BE MATERIALLY ADVERSELY     AFFECTED         The <font color="blue">development</font> of new or <font color="blue">enhanced products</font> is a complex and uncertain     process that requires the accurate <font color="blue">anticipation</font> of <font color="blue">technological</font> and market     trends,  as well as precise <font color="blue">technological</font> execution</td>
    </tr>
    <tr>
      <td>We may experience     design, <font color="blue">development</font>, implementation and other <font color="blue">difficult</font>ies that <font color="blue">could delay</font>     or prevent our <font color="blue">introduction</font> of new or <font color="blue">enhanced products</font>, or products that we     may  develop,  <font color="blue">manufacture</font>  or market with <font color="blue">third parties</font> or affect the     performance of our <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">difficult</font>ies and <font color="blue">delays may</font>     cause expenses to increase and our <font color="blue">product sales</font> to fluctuate</td>
    </tr>
    <tr>
      <td>In addition,     if we experience design, <font color="blue">development</font> or implementation <font color="blue">difficult</font>ies in     developing, <font color="blue">manufacturing</font>, distributing or marketing these <font color="blue">instruments</font>, we     would  sell  fewer of our products and our business <font color="blue">prospects would</font> be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>These changes     could  <font color="blue">facilitate</font>  the <font color="blue">market demand</font> for our new or <font color="blue">enhanced products</font>,     including  the  need  for  products that could be utilized in clinical     point-of-care  sites and field-testing of <font color="blue"><font color="blue">environment</font>al samples</font> in the     <font color="blue">biosecurity</font>  market</td>
    </tr>
    <tr>
      <td>If <font color="blue">market demand</font> does not change or evolve as we     anticipate or if we are not able to develop products that meet the evolving     <font color="blue">market demand</font>, our business <font color="blue">prospects would</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>In addition, the markets for our products are <font color="blue">characterized by evolving</font>     <font color="blue">industry standards</font> and <font color="blue"><font color="blue">government</font> <font color="blue">regulations</font></font>, the need for updated and     <font color="blue">effective</font> <font color="blue">technology</font> and new product <font color="blue">introduction</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>     in part upon our ability to profitably enhance <font color="blue">existing products</font> and develop     and introduce <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>We may not be able to avoid the obsolescence of     our <font color="blue">products due</font> to <font color="blue">technological</font> change and evolving <font color="blue">industry standards</font> and     <font color="blue"><font color="blue">government</font> <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>If we experience design, <font color="blue">development</font>, implementation or other <font color="blue">difficult</font>ies     that delay or prevent our <font color="blue">introduction</font> of new or <font color="blue">enhanced products</font> or if the     markets change or evolve in an <font color="blue">unexpected manner</font>, our business could be     <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>VACCINE DEVELOPMENT IS A LONG, EXPENSIVE AND UNCERTAIN PROCESS, AND DELAY OR     FAILURE CAN OCCUR AT ANY STAGE OF THE PROCESS         To  develop  vaccine  <font color="blue">candidates</font>,  we must provide the FDA and foreign     <font color="blue">regulatory</font> <font color="blue">authorities</font> with <font color="blue">clinical data</font> that <font color="blue">demonstrates</font> adequate safety     and <font color="blue">immune response</font></td>
    </tr>
    <tr>
      <td><font color="blue">Statistically </font><font color="blue">significant</font> <font color="blue"><font color="blue">effective</font>ness</font> of our vaccine     product <font color="blue">candidates</font> cannot be <font color="blue">demonstrated</font> in humans, but instead must be     <font color="blue">demonstrated</font>,  in  part, <font color="blue">by utilizing <font color="blue">animal models</font></font> before they can be     approved for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>Vaccine <font color="blue">development</font> to <font color="blue">show adequate evidence</font>     of <font color="blue"><font color="blue">effective</font>ness</font> in <font color="blue">animal models</font> and safety and <font color="blue">immune response</font> in humans     is a long, expensive and <font color="blue">uncertain process</font>, and delay or failure can occur     at  any  stage  of our <font color="blue">animal studies</font> or <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Any delay or     <font color="blue">significant</font> adverse clinical events arising during any of our clinical     trials  <font color="blue">could force us</font> to abandon a <font color="blue">vaccine candidate altogether</font> or to     conduct <font color="blue">additional</font> <font color="blue">clinical trials</font> in order to obtain <font color="blue">approval from</font> the FDA     or foreign <font color="blue">regulatory</font> bodies</td>
    </tr>
    <tr>
      <td>These <font color="blue">development</font> efforts and <font color="blue">clinical trials</font>     are lengthy and expensive and the outcome is uncertain</td>
    </tr>
    <tr>
      <td>If we are unable to     <font color="blue">successfully</font> develop our vaccine <font color="blue">candidates</font>, our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>WE EXPECT TO RELY ON SALES OF THE M-SERIES PRODUCT FAMILY FOR A SIGNIFICANT     PORTION OF OUR REVENUES, AND A DECLINE IN SALES OF THESE PRODUCTS COULD     CAUSE  ADVERSE  FINANCIAL  RESULTS  AND NEGATIVELY AFFECT OUR BUSINESS     PROSPECTS         We expect to derive a <font color="blue">significant</font> portion of our <font color="blue">revenues from sales</font> of     M-SERIES products</td>
    </tr>
    <tr>
      <td>Our current and <font color="blue">potential life science customers</font> are from     the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> industries and are subject to risks     <font color="blue">faced by</font> those         29       ______________________________________________________________________         industries, including the <font color="blue">availability</font> of capital, reduction and delays in     research  and  <font color="blue">development</font> expenditures, <font color="blue">government</font> regulation and the     <font color="blue">uncertainty</font> resulting from <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>In addition, the ongoing     <font color="blue">consolidation</font> of the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> industries could     reduce the number of <font color="blue">potential customers</font> and they may develop their own     <font color="blue">competing products</font> or in-house capabilities</td>
    </tr>
    <tr>
      <td>Any factor <font color="blue">adversely</font> affecting the pricing or demand of M-SERIES products,     including market <font color="blue">acceptance</font> of <font color="blue">competing products</font>, could cause our revenues     to decline, resulting in <font color="blue">adverse financial</font> results and <font color="blue">negatively affecting</font>     our business prospects</td>
    </tr>
    <tr>
      <td>Additionally, we intend to market M-SERIES products in markets in which we     have little or no experience</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font> market the     M-SERIES family of products in those markets, <font color="blue">which could</font> cause an adverse     <font color="blue">affect on</font> our business prospects</td>
    </tr>
    <tr>
      <td>THE ACCOMPANYING CONSOLIDATED FINANCIAL STATEMENTS FOR FISCAL YEAR 2004 MAY     NOT  NECESSARILY  BE  INDICATIVE OF OUR FINANCIAL POSITION, RESULTS OF     OPERATIONS OR CASH FLOWS HAD WE OPERATED ON A STAND-ALONE BASIS         Until February 13, 2004, our assets and <font color="blue">businesses</font> had <font color="blue">historically been</font>     owned,  operated  and  fully  integrated  with  IGEN Our <font color="blue">accompanying</font>     <font color="blue"><font color="blue">consolidated</font> <font color="blue">financial statements</font></font> for fiscal year 2004 have been prepared     and are <font color="blue">presented as</font> if we had been operating as a separate entity</td>
    </tr>
    <tr>
      <td>In order     to <font color="blue">fairly present</font> our operating results, these <font color="blue"><font color="blue">financial statements</font> reflect</font>     the <font color="blue">application</font> of certain estimates and <font color="blue">allocations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">consolidated</font>     statements of <font color="blue">operations</font> for fiscal 2004 include all revenues and costs that     are <font color="blue">directly attributable</font> to our <font color="blue">businesses</font>, <font color="blue">as well as certain</font> expenses of     IGEN  that  have <font color="blue">been allocated</font> to <font color="blue">us using various assumptions</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>expenses include an allocated share of general and <font color="blue">administrative salaries</font>     <font color="blue">as well as certain</font> other shared costs (primarily <font color="blue">facility</font>, human resources,     legal, accounting and other <font color="blue">administrative costs</font>) which were <font color="blue">allocated based</font>     upon  percentage of <font color="blue">total revenue</font> or percentage of total headcount, as     <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>While <font color="blue">management</font> believes that the <font color="blue">allocation methodologies</font> are     reasonable and <font color="blue">appropriate</font>, <font color="blue">different</font> <font color="blue">allocation methodologies</font> would result     in changes to our operating results for fiscal year 2004</td>
    </tr>
    <tr>
      <td>Upon <font color="blue">completion</font> of the merger and related <font color="blue"><font color="blue">transactions</font> between</font> Roche and     IGEN, we became an in<font color="blue">dependent</font>, publicly-traded company and operate on a     stand-alone  basis</td>
    </tr>
    <tr>
      <td>The  financial  information  in  the <font color="blue">accompanying</font>     <font color="blue">consolidated</font>  <font color="blue">financial statements</font> for fiscal 2004 may not reflect our     <font color="blue">financial position</font>, results of <font color="blue">operations</font> and <font color="blue">cash flows</font> in the future or     what they would have been had we been operating as a stand-alone entity in     the past</td>
    </tr>
    <tr>
      <td>MST HAS PURCHASED OUR INTERESTS IN MSD BUT THERE IS NO ASSURANCE THAT WE     WILL RECEIVE THE FULL PURCHASE PRICE         MST purchased our <font color="blue">entire interests</font> in MSD and is required to pay us the     outstanding  purchase  price  over  time,  plus simple (cumulated, not     compounded) interest at the fixed annual rate of 5dtta5prca</td>
    </tr>
    <tr>
      <td>The <font color="blue">purchase price</font> is     <font color="blue">payable over</font> time in installments equal to the sum of 5prca of MSD net sales,     as determined in <font color="blue">accordance with</font> the MSD <font color="blue"><font color="blue">agreement</font>s</font>, and 20prca of the net     proceeds realized by MSD from the sale of its debt or <font color="blue">equity securities</font> in     any third-party financing after the date of the sale of our interests in     MSD We received a <font color="blue">prepayment</font> credit of dlra2dtta0 million against our payment     <font color="blue">obligations</font> to MSD in <font color="blue"><font color="blue">connection</font> with</font> the settlement, and therefore the     initial installment payments are being applied against this credit and not     paid to us in cash</td>
    </tr>
    <tr>
      <td>No <font color="blue">further cash payments will</font> be <font color="blue">payable by</font> MSD to us     pursuant to the <font color="blue">buyout until</font> the <font color="blue">prepayment</font> credit, which has a balance of     dlra1dtta2 million at March 31, 2006, is no longer deemed outstanding</td>
    </tr>
    <tr>
      <td>Because the <font color="blue">purchase price</font> is payable only out of a percentage of MSD’s net     sales or <font color="blue">future <font color="blue">financings</font></font>, our receipt of the <font color="blue">purchase price</font> is <font color="blue">dependent</font>     on MSD’s <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>In the event sufficient future net sales of MSD     or third-party <font color="blue">financings</font> do not <font color="blue">materialize</font>, we will not receive the full     <font color="blue">purchase price</font> for our interests in MSD         We have recorded the <font color="blue">net <font color="blue">present value</font></font> of the <font color="blue">receivable due</font> to us from the     sale of our interests in MSD in the amount of dlra5dtta7 million at March 31,     2006</td>
    </tr>
    <tr>
      <td>If we do not receive the full <font color="blue">purchase price</font> over time, from the sale     of our interests in MSD, we would be required to write off the <font color="blue">remaining net</font>     <font color="blue">present value</font> or record an <font color="blue">impairment</font> of the value of the receivable</td>
    </tr>
    <tr>
      <td>Such a     write-off or the recording of such an <font color="blue">impairment</font> could have a material     adverse effect on our future results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>30       ______________________________________________________________________           OUR COMPETITORS AND POTENTIAL COMPETITORS MAY HAVE OR DEVELOP DIAGNOSTIC AND     VACCINE PRODUCTS AND TECHNOLOGIES THAT ARE MORE ATTRACTIVE THAN OUR EXISTING     OR FUTURE DIAGNOSTIC AND VACCINE PRODUCTS         Our business will be subject to intensive <font color="blue">competition</font> from established     companies,  <font color="blue">development</font>  stage  companies  and  research  and academic     <font color="blue">institutions</font>, and we expect this <font color="blue">competition</font> to intensify</td>
    </tr>
    <tr>
      <td>Many of these     companies and <font color="blue">institutions</font> have one or more <font color="blue">competitive</font> <font color="blue">advantages</font> over us,     including, among other things:         •       more money to invest;         •       more established <font color="blue">diagnostic</font> or <font color="blue">vaccine products</font>;         •       longer-standing <font color="blue">relationships</font> with customers;         •       greater expertise and resources in developing, <font color="blue">manufacturing</font>, marketing and     selling <font color="blue">diagnostic</font> or <font color="blue">vaccine products</font>;         •       a larger, more experienced workforce; and         •       more experience in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">clinical testing</font> or     <font color="blue">vaccine products</font></td>
    </tr>
    <tr>
      <td>As  a result, our <font color="blue">competitors</font> may develop, <font color="blue">manufacture</font>, market or sell     <font color="blue">diagnostic</font> or <font color="blue">vaccine products</font> that are more <font color="blue">effective</font> or <font color="blue">commercially</font>     attractive than our current or future <font color="blue">diagnostic</font> or <font color="blue">vaccine products</font></td>
    </tr>
    <tr>
      <td>In     addition, these <font color="blue">competitors</font> may offer broader product lines, discounts and     may have greater name <font color="blue">recognition</font> than us</td>
    </tr>
    <tr>
      <td>Furthermore, we compete against     companies that utilize ECL <font color="blue">technology</font> licensed to <font color="blue">them by us</font>, including     Roche and MSD         As  a  result,  we may not be able to compete <font color="blue">successfully</font> against our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>This could have a material adverse effect on our business,     <font color="blue">financial condition</font> and revenues</td>
    </tr>
    <tr>
      <td>WE HAVE LIMITED MANUFACTURING EXPERIENCE, WHICH PUTS US AT A COMPETITIVE     DISADVANTAGE AND COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS,     FINANCIAL CONDITION AND REVENUE         We lack experience in large-scale <font color="blue">manufacturing</font> and have no experience in     the <font color="blue">manufacturing</font> of clinical <font color="blue">diagnostic</font> or <font color="blue">vaccine products</font>, <font color="blue">which could</font>     hamper our ability to <font color="blue">manufacture</font> <font color="blue">existing products</font> or <font color="blue">new products</font> that we     develop</td>
    </tr>
    <tr>
      <td>We have two options to address this <font color="blue">competitive</font> <font color="blue">disadvantage</font></td>
    </tr>
    <tr>
      <td>First, we <font color="blue">could expand</font> our internal ability to <font color="blue">manufacture</font> products, which,     to date, has <font color="blue">only been done</font> in a limited way</td>
    </tr>
    <tr>
      <td>Second, we <font color="blue">could <font color="blue">contract with</font></font>     a <font color="blue">third party</font> to <font color="blue">manufacture</font> products for us <font color="blue">based on</font> our <font color="blue">technology</font>, which,     to date, we have not done</td>
    </tr>
    <tr>
      <td>If  we are unable to expand our own <font color="blue">manufacturing</font> capability or find a     suitable <font color="blue">manufacture</font>r on acceptable terms in a <font color="blue">timely manner</font>, we may be     unable  to  meet  demand for <font color="blue">existing products</font> and could be delayed in     introducing <font color="blue">new products</font> to the market</td>
    </tr>
    <tr>
      <td>Failure to meet demand for existing     products or delays in introducing <font color="blue">new products</font> could put us at a <font color="blue">competitive</font>     <font color="blue">disadvantage</font> and could have a material adverse effect on our business,     <font color="blue">financial condition</font> and revenue</td>
    </tr>
    <tr>
      <td>WE HAVE LIMITED MANUFACTURING FACILITIES FOR OUR CURRENT PRODUCTS AND WE MAY     NOT FIND ADDITIONAL FACILITIES SUITABLE FOR FUTURE GROWTH, WHICH COULD     MATERIALLY ADVERSELY AFFECT OUR BUSINESS AND PROSPECTS         We <font color="blue">face risks inherent</font> in operating a <font color="blue">single <font color="blue">facility</font></font> for the <font color="blue">manufacture</font> of     our <font color="blue">current products</font></td>
    </tr>
    <tr>
      <td>We do not have       <font color="blue">alternative</font>  production  <font color="blue"><font color="blue">facilities</font> available should</font> our Gaithersburg,     Maryland <font color="blue">manufacturing</font> <font color="blue">facility</font> cease to function</td>
    </tr>
    <tr>
      <td>If our <font color="blue">facility</font> were not     operational for an <font color="blue">extended period</font> of time, including due to an unforeseen     plant shutdown, then our business and <font color="blue">future <font color="blue">prospects could</font></font> be <font color="blue">materially</font>     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>In addition, we may need to expand and enhance our research, <font color="blue">development</font> and     <font color="blue">production <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td>We may also be         31       ______________________________________________________________________         required to make material <font color="blue">capital expenditures at</font> a new <font color="blue">facility</font> at a time     when we have limited <font color="blue">capital resources available</font> to us</td>
    </tr>
    <tr>
      <td>We may also experience <font color="blue">difficult</font>ies or delays in <font color="blue">integrating</font> our <font color="blue">operations</font>     into  new  <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">difficult</font>ies might include delays in the     <font color="blue">availability</font>  of  a new <font color="blue">facility</font> or problems <font color="blue">associated with</font> equipment     <font color="blue">installation</font></td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">facility</font> that we obtain for production of     vaccines, <font color="blue">clinical testing</font> or <font color="blue">biosecurity</font> products will be subject, on an     <font color="blue">ongoing basis</font>, to a variety of <font color="blue">regulatory</font> <font color="blue">requirements</font> including quality     systems <font color="blue">regulations</font>, international quality standards and other <font color="blue">regulatory</font>     standards</td>
    </tr>
    <tr>
      <td>We  may encounter <font color="blue">difficult</font>ies expanding our <font color="blue">manufacturing</font>     <font color="blue">operations</font> in <font color="blue">accordance with</font> these <font color="blue">regulations</font> and standards, <font color="blue">which could</font>     result in <font color="blue">manufacturing</font> delays and an <font color="blue">inability</font> to <font color="blue">meet product demand</font> and     our business <font color="blue">prospects could</font> be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If we are unable to pay for <font color="blue">facility</font> <font color="blue">enhancements</font> and <font color="blue">improvements</font> to meet     our <font color="blue">future growth</font> needs, our business <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>WE HAVE NO EXPERIENCE SELLING, MARKETING OR DISTRIBUTING CLINICAL DIAGNOSTIC     OR VACCINE PRODUCTS OUR FAILURE TO ESTABLISH AN EFFECTIVE SALES FORCE OR TO     ESTABLISH AN EFFICIENT DISTRIBUTION SYSTEM FOR OUR CLINICAL DIAGNOSTIC OR     VACCINE PRODUCTS COULD MATERIALLY ADVERSELY AFFECT OUR BUSINESS PROSPECTS     AND REVENUES         We need to develop selling, marketing and <font color="blue">distribution</font> capabilities for our     planned  clinical  <font color="blue">diagnostic</font> and <font color="blue">vaccine products</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">market clinical</font>     <font color="blue">diagnostic</font> or <font color="blue">vaccine products</font> directly to customers, and not through a     licensee or <font color="blue">third party</font> distributor or <font color="blue">collaborator</font>, we will need to develop     a substantial <font color="blue"><font color="blue">sales force</font> with technical expertise</font></td>
    </tr>
    <tr>
      <td>We will also need to     establish a <font color="blue">distribution</font> system to support our <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>Alternatively,     we <font color="blue">could license</font> or <font color="blue">contract with</font> another company to <font color="blue">provide sales</font> and     <font color="blue">distribution</font> services for our products</td>
    </tr>
    <tr>
      <td>We may not be able to develop a     <font color="blue">sufficient sales</font> and <font color="blue">distribution</font> force or find a <font color="blue">suitable company</font> to fill     that role for us, <font color="blue">which could</font> <font color="blue">materially</font> <font color="blue">adversely</font> affect our business     prospects and revenues</td>
    </tr>
    <tr>
      <td>FAILURE TO MANAGE OUR GROWTH COULD ADVERSELY AFFECT OUR BUSINESS         We  expect  to <font color="blue">grow by increasing</font> our presence in <font color="blue">existing markets</font> and     introducing <font color="blue">new products</font> we develop <font color="blue">into new potential markets</font></td>
    </tr>
    <tr>
      <td>Our growth     strategy  will  place a strain on our <font color="blue">management</font> and our operating and     <font color="blue">financial systems</font></td>
    </tr>
    <tr>
      <td>As  we  grow,  our  personnel, systems, <font color="blue">manufacturing</font> capabilities and     resources, procedures and <font color="blue">controls may</font> be inadequate to <font color="blue">support future</font>     <font color="blue">operations</font> and we will need to hire, train and retain <font color="blue">additional</font> personnel</td>
    </tr>
    <tr>
      <td>We  may  also  need to improve and expand our financial and <font color="blue">management</font>     controls, reporting systems and operating <font color="blue">systems as well as</font> other aspects     of our <font color="blue">infrastructure</font>, including research and <font color="blue">development</font> or <font color="blue">manufacturing</font>     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue">difficult</font>ies <font color="blue">integrating</font> <font color="blue">additional</font> personnel,     as well as improving, expanding and <font color="blue">integrating</font> new systems or <font color="blue">facilities</font>,     <font color="blue">which could</font> <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>THE SUCCESS OF OUR BUSINESS DEPENDS ON PATENTS THAT WILL EXPIRE OVER TIME     AND THAT MUST BE ACTIVELY PURSUED, OBTAINED, MAINTAINED AND PROTECTED         Our business success or <font color="blue">failure will depend</font>, in part, on our ability to     pursue, obtain, and maintain <font color="blue">adequate <font color="blue">patent protection</font></font> for ECL <font color="blue">technology</font>,     vaccines and our other <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patents may</font> not <font color="blue">adequately protect</font>     our <font color="blue">technology</font> from being used by our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends heavily on patents</font> that will expire over time and may     be challenged or circumvented by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Patents allow us, for a time,     to <font color="blue">prevent others from using</font> our <font color="blue">inventions</font> to <font color="blue">compete <font color="blue">against us</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font><font color="blue">may challenge</font> or seek to invalidate patents or <font color="blue">circumvent valid</font>     claims in patents, all of <font color="blue">which could</font> make it <font color="blue">necessary</font> for us to defend our     patents in <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font><font color="blue">over patents poses</font> the <font color="blue">following risks</font> to     our business:         •       <font color="blue">litigation</font> costs can be extremely high, <font color="blue">which could</font> drain our financial     resources; and         •       <font color="blue">litigation</font> over our <font color="blue">patents could discourage</font> other <font color="blue">companies from</font> working     with us to develop and <font color="blue">market new</font>         32       ______________________________________________________________________         products <font color="blue">based on</font> the <font color="blue">technology</font> covered by those <font color="blue">disputed patents</font></td>
    </tr>
    <tr>
      <td>If  we lose some <font color="blue">patent protection</font>, our <font color="blue">competitive</font> advantage could be     eroded, <font color="blue">third parties</font> may be able to use our <font color="blue">technology</font> without paying us     and  our <font color="blue">financial condition</font> and business <font color="blue">prospects would</font> be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>OUR BUSINESS COULD BE HARMED IF WE HAVE FUTURE DISAGREEMENTS WITH ROCHE OVER     THE SCOPE OF THE LICENSE AGREEMENT         Roche, <font color="blue">through one</font> of its <font color="blue">affiliates</font>, has <font color="blue">been licensed by us</font> to exploit ECL     <font color="blue">technology</font>, subject to the <font color="blue">limitations</font> of the <font color="blue">license <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>the terms of the <font color="blue">license <font color="blue">agreement</font></font> were negotiated in an effort to minimize     the areas of <font color="blue">potential <font color="blue">future disputes</font></font>, there are <font color="blue">no assurances</font> that we and     Roche <font color="blue">will continue</font> to agree on the scope, permitted use and other material     terms of the <font color="blue">license <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">disputes with</font> Roche, or any licensee,     over the scope of the <font color="blue">license <font color="blue">agreement</font></font>, such as <font color="blue">disputes over</font> the field,     the  types of products that Roche is permitted to develop and sell, or     royalties  owed, including payments for out-of-field sales by Roche of     licensed products that employ ECL <font color="blue">technology</font> and which are outside the     licensed field, might lead to lengthy and costly <font color="blue">legal proceedings</font>, which     could  <font color="blue">adversely</font>  affect  our  <font color="blue">financial condition</font> and future business     prospects</td>
    </tr>
    <tr>
      <td>OUR BUSINESS COULD BE HARMED IF WE INFRINGE, OR OUR LICENSEES ARE ALLEGED TO     HAVE INFRINGED, THE INTELLECTUAL PROPERTY OF OTHERS         If our products or services were to infringe the <font color="blue">intellectual property</font>     (including <font color="blue">patent rights</font>) of others, we or our licensees could:         •       be required to alter, or <font color="blue">abandon products</font> or processes;         •       be required to obtain a <font color="blue">license from</font> the <font color="blue">intellectual property</font> holder;         •       <font color="blue">lose customers</font> that are reluctant to <font color="blue">continue using</font> our or our licensees’     products or services;         •       be forced to abandon <font color="blue">development</font> work <font color="blue">with respect</font> to these products; and         •       be required to pay damages that could be substantial</td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">licensees infringe</font> the <font color="blue">intellectual property</font> (including patent     rights) of others, our business could be damaged if we were unable to make     <font color="blue">necessary</font> alterations or obtain a <font color="blue">necessary</font> license on acceptable terms, if     at all</td>
    </tr>
    <tr>
      <td>In addition, if our products or services were alleged to have infringed the     <font color="blue">intellectual property</font> (including <font color="blue">patent rights</font>) of others, we would be     forced to <font color="blue">defend ourselves</font> in <font color="blue">litigation</font> and might be <font color="blue">enjoined from further</font>     sale of our products or required to <font color="blue">pay monetary damages</font> or amounts in     settlement of the suit, <font color="blue">which could</font> <font color="blue">adversely</font> affect our prospects, drain     our <font color="blue">financial resources</font> and discourage other <font color="blue">companies from</font> working with us</td>
    </tr>
    <tr>
      <td>WE INTEND TO DEVELOP PRODUCTS THAT ARE BASED ON PATENTS AND TECHNOLOGY THAT     WE HAVE LICENSED FROM OTHERS AND THE OWNERS OF THOSE PATENTS AND TECHNOLOGY     MIGHT CLAIM THAT PRODUCTS DEVELOPED OR SOLD BY US VIOLATE THOSE LICENSES     ADDITIONALLY, A THIRD PARTY MIGHT OBJECT TO A LICENSE THAT WE HOLD OR TO THE     SCOPE OF THE LICENSE GRANTED TO US         Our success or <font color="blue">failure will also depend</font>, in part, on the <font color="blue">patent rights</font> and     <font color="blue">technology</font> of others, including patents and <font color="blue">technology</font> being licensed to us     from <font color="blue">affiliates</font> of Roche</td>
    </tr>
    <tr>
      <td>We have been licensed by <font color="blue">affiliates</font> of Roche to     exploit  certain  <font color="blue">improvements</font>  from <font color="blue">Roche Diagnostics </font>and certain PCR     <font color="blue">technology</font>,  subject to certain <font color="blue">limitations</font></td>
    </tr>
    <tr>
      <td>Although the terms of the     <font color="blue">improvements</font>  license  <font color="blue">agreement</font>  and  the PCR license <font color="blue"><font color="blue">agreement</font>s</font> were     negotiated in an effort to minimize the areas of <font color="blue">potential <font color="blue">future disputes</font></font>,     there are <font color="blue">no assurances</font> that we and Roche <font color="blue">will continue</font> to agree on the     scope, permitted use and other material terms of the <font color="blue">improvements</font> license     <font color="blue">agreement</font> or the PCR license <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">disputes with</font> Roche over the     scope, permitted use, <font color="blue">obligations</font> owed and other material terms of the     <font color="blue">improvements</font>  <font color="blue">license <font color="blue">agreement</font></font> or the PCR license <font color="blue"><font color="blue">agreement</font>s</font>, such as     <font color="blue">disputes over</font> the field, types of products that we are       ______________________________________________________________________         33         permitted to develop and sell, other <font color="blue">obligations</font> may lead to lengthy and     costly  <font color="blue">legal proceedings</font>, or <font color="blue">could interfere with</font> or <font color="blue">preclude us from</font>     proceeding  with  one  or more <font color="blue">development</font> programs, <font color="blue">whether conducted</font>     in<font color="blue">dependent</font>ly or through a <font color="blue">collaborative arrangement</font></td>
    </tr>
    <tr>
      <td>In addition, third     <font color="blue">parties may</font> object to the scope, permitted use and other material terms of     one or more of the <font color="blue">licenses granted</font> to <font color="blue">us by certain</font> Roche <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td>We also license <font color="blue">technology</font> from other companies and academic <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Because access to this <font color="blue">technology</font> is <font color="blue">necessary</font> to operate our business, we     must be certain that we <font color="blue">comply with</font> these license <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our business     could be harmed if we breached any of these license <font color="blue"><font color="blue">agreement</font>s</font> and lost the     rights  to  use this patented <font color="blue">technology</font> or if we were unable to renew     <font color="blue">existing licenses on</font> acceptable terms, if at all, or get <font color="blue">additional</font> licenses     that we may need on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>In addition, we may need to     litigate  the  scope  and  validity of patents held by others and such     <font color="blue">litigation</font> could be a substantial cost for us</td>
    </tr>
    <tr>
      <td>WE AND MSD MAY HAVE DIFFERENT VIEWS OF THE SCOPE OF THE EXCLUSIVE LICENSE TO     OUR TECHNOLOGY PREVIOUSLY GRANTED TO MSD AND THE SCOPE OF MSD’S RIGHTS UNDER     THE FORMER JOINT VENTURE AGREEMENT WITH US, WHICH COULD AFFECT OUR ABILITY     TO EXPAND OUR BUSINESS DIRECTLY OR THROUGH COLLABORATIONS         We intend to expand our business through internal <font color="blue">development</font> programs and     <font color="blue">through new</font> or expanded <font color="blue">collaborative arrangement</font>s</td>
    </tr>
    <tr>
      <td>MSD may view the scope     of its <font color="blue">exclusive license</font> and other <font color="blue">rights under</font> its <font color="blue">license <font color="blue">agreement</font></font> and     other <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with us</font> in a way that <font color="blue">interferes with</font> or <font color="blue">precludes us from</font>     <font color="blue">proceeding with one</font> or more <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>There are <font color="blue">no assurances</font>     that MSD will not object to our future business plans, <font color="blue">whether conducted</font>     in<font color="blue">dependent</font>ly or through a <font color="blue">collaborative arrangement</font></td>
    </tr>
    <tr>
      <td>Additionally, MSD may     believe that we must obtain MSD’s <font color="blue">consent prior</font> to <font color="blue">entering into proposed</font>     <font color="blue">collaborative arrangement</font>s</td>
    </tr>
    <tr>
      <td>The other party to a proposed <font color="blue">collaboration</font> with     us may also require us to obtain MSD’s consent to avoid any <font color="blue">future disputes</font>     or dis<font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>For example, in <font color="blue"><font color="blue">connection</font> with</font> the merger and related     <font color="blue">transactions</font>, Roche required IGEN to obtain MSD’s consent to the execution     and delivery of the <font color="blue">license <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>If we are required to obtain MSD’s     consent for any reason, there are <font color="blue">no assurances</font> that we will be able to     obtain that <font color="blue">consent at</font> all or on terms that would not have an adverse effect     on our business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition,     if we choose not to obtain MSD’s consent, MSD <font color="blue">may sue us</font> to <font color="blue">enforce rights</font>     it believes it has</td>
    </tr>
    <tr>
      <td>Such a lawsuit could <font color="blue">materially</font> harm our business and     future business prospects</td>
    </tr>
    <tr>
      <td>WE RELY ON TRADE SECRETS AND OTHER INFORMATION THAT CANNOT BE PROTECTED BY     PATENTS,  WHICH  COULD  HARM OUR BUSINESS IF THEY WERE DISCLOSED TO OR     INDEPENDENTLY DEVELOPED BY OTHERS         In addition to patents, we also rely in our business <font color="blue">on <font color="blue">trade secrets</font></font>,     know-how  and  other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>If this information were     disclosed to or in<font color="blue">dependent</font>ly developed by <font color="blue">competitors</font>, our business would     suffer</td>
    </tr>
    <tr>
      <td>We  seek  to  protect  this  information,  in  part,  <font color="blue">by entering into</font>     <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font> with licensees, employees and <font color="blue">consultants</font> that     prohibit these <font color="blue">parties from</font> disclosing our <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue">agreement</font>s</font>  may not <font color="blue">provide adequate protection</font> for our <font color="blue">trade secrets</font>,     know-how and other <font color="blue">proprietary</font> information or ensure that the information we     share  with  others  during  the  course  of  our business will remain     <font color="blue">confidential</font></td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient legal remedies under</font> the <font color="blue"><font color="blue">agreement</font>s</font>     or  otherwise to correct or compensate for <font color="blue"><font color="blue">unauthorized</font> <font color="blue">disclosure</font>s</font> or     <font color="blue">sufficient resources</font> to <font color="blue">seek redress</font></td>
    </tr>
    <tr>
      <td>If  we  are  not  able to be <font color="blue">adequately redressed</font> for the <font color="blue">unauthorized</font>     <font color="blue">disclosure</font> of our <font color="blue">trade secrets</font>, know-how or other <font color="blue">proprietary</font> information,     our <font color="blue">competitive</font> position may be undermined and our business may suffer</td>
    </tr>
    <tr>
      <td>WE  DEPEND  ON A LIMITED NUMBER OF SUPPLIERS FOR MATERIALS USED IN THE     MANUFACTURING OF OUR PRODUCTS, AND ANY INTERRUPTION IN THE SUPPLY OF THOSE     MATERIALS COULD HAMPER OUR ABILITY TO MANUFACTURE PRODUCTS AND MEET CUSTOMER     ORDERS         We <font color="blue">depend on vendors</font> to <font color="blue">supply key materials</font> that we use in our products</td>
    </tr>
    <tr>
      <td>From time     to time, <font color="blue">suppliers may extend lead</font> time, <font color="blue">limit supplies</font> or <font color="blue">increase prices</font>     due to <font color="blue">capacity constraints</font> or other factors</td>
    </tr>
    <tr>
      <td>In the event of a reduction     in, <font color="blue">interruption</font> of, or <font color="blue">degradation</font> in, the quality of the supply of any of     the materials required by us, or an increase in the cost of obtaining those     materials, we would be         34       ______________________________________________________________________         forced to locate an <font color="blue">alternative</font> source of supply</td>
    </tr>
    <tr>
      <td>If no <font color="blue">alternative</font> source     were available or if an <font color="blue">alternative</font> source were not <font color="blue">available on</font> a timely     basis, at a reasonable cost or otherwise on acceptable terms, our ability to     <font color="blue">manufacture</font> one or more of our products would be delayed or halted</td>
    </tr>
    <tr>
      <td>Any changes in sources of supply may require <font color="blue">additional</font> engineering or     technical <font color="blue">development</font> to <font color="blue">ensure consistent</font> and acceptable performance of our     products</td>
    </tr>
    <tr>
      <td>If any of these events occur, our <font color="blue">product costs may increase</font>, we     might be unable to deliver products in a <font color="blue">timely fashion</font>, we <font color="blue">could lose sales</font>     <font color="blue">as well as customers</font>, and our business would be <font color="blue">significant</font>ly harmed as a     result</td>
    </tr>
    <tr>
      <td>WE DEPEND ON HIGHLY TRAINED AND SKILLED EMPLOYEES AND MANAGEMENT, AND WE MAY     NOT  BE  ABLE  TO ATTRACT AND RETAIN SUFFICIENT PERSONNEL, WHICH COULD     ADVERSELY AFFECT OUR BUSINESS         We need to hire staff and retain our staff, both of which are <font color="blue">difficult</font> in a     <font color="blue">competitive</font> marketplace</td>
    </tr>
    <tr>
      <td>Because we are a <font color="blue">technology</font> company, we depend     <font color="blue">heavily on <font color="blue">scientists</font></font> and engineers to develop products and to build a     successful business</td>
    </tr>
    <tr>
      <td>Research and <font color="blue">development</font> efforts <font color="blue">could suffer</font> if we are     not able to hire and retain enough <font color="blue">qualified <font color="blue">scientists</font></font> and engineers, which     would  <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> other <font color="blue">technology</font>     companies and research and academic <font color="blue">institutions</font> for experienced <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>Many of these companies and <font color="blue">institutions</font> have greater resources than we do     and thus may be in a <font color="blue">better position</font> to attract desirable <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In  addition  to  <font color="blue">scientists</font>,  we  also need to <font color="blue">hire managers</font> who have     <font color="blue">regulatory</font>, <font color="blue">manufacturing</font> and <font color="blue">marketing capabilities</font></td>
    </tr>
    <tr>
      <td>If we are not able to     <font color="blue">hire managers</font> with these skills, or develop expertise in these areas, our     business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>OUR ABILITY TO DEVELOP PRODUCTS MAY BE NEGATIVELY AFFECTED BY SOCIAL ISSUES     RELATING TO ANIMAL TESTING         Our research and <font color="blue">development</font> activities have involved, and in the future     <font color="blue">might involve</font>, limited testing in mice and rats</td>
    </tr>
    <tr>
      <td>In addition, testing in the     future  may  involve  other  animals</td>
    </tr>
    <tr>
      <td>Animal  <font color="blue">rights groups</font> and other     <font color="blue">organizations</font>  and  <font color="blue">individuals</font>  have attempted to <font color="blue">stop animal testing</font>     <font color="blue">activities by pressing</font> for <font color="blue">legislation</font> and regulation of <font color="blue">such activities</font> and     by other means</td>
    </tr>
    <tr>
      <td>Our ability to develop <font color="blue">products may</font> be <font color="blue">negatively affected</font>     by a <font color="blue">ban on animal testing</font> or <font color="blue">by action taken by groups</font> or <font color="blue">individuals</font>     opposed to these tests</td>
    </tr>
    <tr>
      <td>Risks Relating to Regulation and <font color="blue">Government </font>Contracts         OUR ABILITY TO OBTAIN AND RETAIN US GOVERNMENT CONTRACTS IS SUBJECT TO     UNCERTAINTIES, AND OUR US GOVERNMENT CONTRACTS MAY BE TERMINATED, WHICH     COULD  MATERIALLY  ADVERSELY AFFECT OUR FINANCIAL CONDITION, OPERATING     RESULTS, BUSINESS AND PROSPECTS         Our ability to secure or retain US <font color="blue"><font color="blue">government</font> contracts</font> is subject to     <font color="blue">uncertainties</font> related to the <font color="blue">government</font>’s future funding commitments</td>
    </tr>
    <tr>
      <td>The     prospects for our <font color="blue">biosecurity</font> business are <font color="blue">also highly sensitive</font> to changes     in national and <font color="blue">international <font color="blue">government</font> policies</font> and <font color="blue">funding priorities</font></td>
    </tr>
    <tr>
      <td>Changes in domestic or foreign <font color="blue">government</font> policies or priorities, including     funding levels through agency or program budget <font color="blue">reductions</font> by the US     Congress  or executive agencies, could <font color="blue">materially</font> <font color="blue">adversely</font> affect our     ability to retain or obtain US <font color="blue"><font color="blue">government</font> contracts</font>, and our business     prospects <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>The US <font color="blue">government</font> can terminate, suspend or modify any of its contracts     <font color="blue">with us either</font> for its convenience or if we <font color="blue">default by failing</font> to perform     under the terms of the <font color="blue">applicable contract</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">termination</font> or suspension for     convenience  could  result  in  our having excess capacity, inventory,     personnel, unreimbursable expenses or charges or other <font color="blue">adverse effects on</font>     our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">termination</font> arising out of our <font color="blue">default could</font>     expose us to claims for damages and may have a material adverse effect on     our ability to compete for future US <font color="blue"><font color="blue">government</font> contracts</font> and orders</td>
    </tr>
    <tr>
      <td>US  <font color="blue">government</font>  <font color="blue">contracts may span one</font> or more years and may include     <font color="blue">multiple renewal options</font> in favor of the US <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>US <font color="blue">government</font>     <font color="blue">agencies generally</font> have the right not to exercise these <font color="blue">option periods</font> for     any reason, including lack of funding, or if the agency is not satisfied     with the counterparty’s performance of the contract</td>
    </tr>
    <tr>
      <td><font color="blue">If the US </font><font color="blue">government</font>     terminates any of our contracts, our <font color="blue">financial condition</font> and operating     results could be <font color="blue">materially</font>         35       ______________________________________________________________________         <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>In addition to unfavorable <font color="blue">termination</font> provisions, certain of our US     <font color="blue"><font color="blue">government</font> contracts</font> contain provisions that grant to the US <font color="blue">government</font> a     non-exclusive,  non-transferable,  irrevocable, paid-up license to use     <font color="blue">inventions</font> made by us in the course of performing <font color="blue">such contracts</font>, or have     such <font color="blue">inventions</font> used by or on behalf of the US <font color="blue">government</font>, for research or     other <font color="blue">government</font> purposes</td>
    </tr>
    <tr>
      <td>New US <font color="blue"><font color="blue">government</font> contracts</font> we <font color="blue">enter into may</font>     also include similar provisions</td>
    </tr>
    <tr>
      <td>WE MUST OBTAIN FDA CLEARANCE OR APPROVAL TO MARKET OUR CLINICAL DIAGNOSTIC     AND VACCINE PRODUCTS, WHICH IS OFTEN COSTLY AND TIME CONSUMING IF WE DO NOT     OBTAIN THE NECESSARY CLEARANCES OR APPROVALS, OUR BUSINESS PROSPECTS WOULD     SUFFER         The <font color="blue">manufacture</font>, packaging, labeling, advertising, promotion, <font color="blue">distribution</font>     and  sale  of clinical <font color="blue">diagnostic</font> products and vaccines are subject to     <font color="blue">government</font>al regulation by national and local <font color="blue">government</font> agencies in the     <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>The FDA regulates many of the areas in which we     conduct  our research and in which we are and expect to be developing,     <font color="blue">manufacturing</font> and <font color="blue">marketing products</font></td>
    </tr>
    <tr>
      <td>In particular, we must obtain FDA     clearance or approval before we can <font color="blue">market clinical</font> <font color="blue">diagnostic</font> or vaccine     products</td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">necessary</font> clearances or approvals is     <font color="blue">often costly</font>, time consuming and uncertain</td>
    </tr>
    <tr>
      <td>Further, clearance or <font color="blue">approval may</font> place substantial     <font color="blue"><font color="blue">restrictions</font> on</font> the <font color="blue">indications</font> for which the <font color="blue">product may</font> be marketed or to     whom it may be marketed</td>
    </tr>
    <tr>
      <td>To obtain <font color="blue">permission from</font> the FDA to <font color="blue">market clinical</font> <font color="blue">diagnostic</font> products in     the US, we, or the companies we work with, will need to either obtain     Section 510(k) pre-market notification clearance or approval of a pre-market     approval <font color="blue">application</font> from the FDA To obtain clearance for marketing, we, or     the companies we work with, must demonstrate substantial equivalence to a     similar <font color="blue">legally marketed product by submitting</font> a pre-market notification to     the FDA The       FDA may require preclinical and <font color="blue">clinical data</font> to support a substantial     equivalence de<font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>Clinical trials for gathering <font color="blue">supporting data</font> can     take <font color="blue">extended period</font>s of time to complete and there can be no assurance that     the FDA will find a device <font color="blue">substantially equivalent</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">successfully</font> demonstrate substantial equivalence, or if we are     required to obtain pre-market approval, we would have to conduct extensive     <font color="blue">clinical testing</font> of these <font color="blue">diagnostic</font> products, <font color="blue">which could</font> take years to     complete</td>
    </tr>
    <tr>
      <td><font color="blue">Extensive </font><font color="blue">testing could involve</font> substantial <font color="blue">additional</font> costs and     might delay bringing clinical <font color="blue">diagnostic</font> products to market, weakening our     <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>If we fail to obtain FDA clearance or approval for new     clinical <font color="blue">diagnostic</font> products altogether, we will be unable to market these     <font color="blue">products at</font> all for <font color="blue">clinical use</font> in the US We may begin to distribute     reagents  <font color="blue">specifically</font> for <font color="blue">research use under</font> an exemption</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA     </font><font color="blue">disagrees with</font> our classification of, or the manner in which we market and     sell those reagents, it may impose <font color="blue"><font color="blue">restrictions</font> on</font> our business <font color="blue">operations</font>     and  subject  us to sanctions that could <font color="blue">adversely</font> affect our business     prospects</td>
    </tr>
    <tr>
      <td>Our vaccine <font color="blue">candidates</font> are in pre-clinical stages of <font color="blue">development</font> and have     not  received  <font color="blue">regulatory</font>  <font color="blue">approval from</font> the FDA or foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font>  to  be  marketed  and sold</td>
    </tr>
    <tr>
      <td>The FDA or foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font>  may refuse to approve an <font color="blue">application</font> if they believe that     applicable  <font color="blue">regulatory</font> criteria are not satisfied and they may require     <font color="blue">additional</font> testing for safety or <font color="blue"><font color="blue">effective</font>ness</font></td>
    </tr>
    <tr>
      <td>WE ARE SUBJECT TO COMPREHENSIVE GOVERNMENT REGULATION, WHICH MAY INVOLVE     SIGNIFICANT COSTS AND MAY RESTRICT OUR ABILITY TO CONDUCT BUSINESS         We expect that certain of our <font color="blue">future products will</font> be subject to continuing     FDA <font color="blue">requirements</font>, including <font color="blue">compliance with</font> the FDA’s Good Manufacturing     Practices and the FDA’s medical device reporting <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We expect that     we may need to spend a substantial amount of money to <font color="blue">comply on</font> an ongoing     basis with <font color="blue"><font color="blue">government</font> <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>agencies, such as the FDA,     Department  of  Homeland  Security,  Department  of  <font color="blue">Commerce  </font>and the     Environmental Protection Agency, or EPA, regulate many of our products as     well as products that we plan to develop, <font color="blue">manufacture</font>, market and sell,     including products for the clinical <font color="blue"><font color="blue">diagnostic</font>s</font>, <font color="blue">biosecurity</font> and industrial     markets</td>
    </tr>
    <tr>
      <td>The costs of complying with <font color="blue">government</font>al <font color="blue">regulations</font> and any     <font color="blue">restrictions</font> that <font color="blue">government</font> agencies might impose could         36       ______________________________________________________________________         have a <font color="blue">significant</font> impact on our business</td>
    </tr>
    <tr>
      <td>If we increase our <font color="blue">manufacturing</font>     and expand our <font color="blue">product offerings</font>, these <font color="blue">costs will increase</font></td>
    </tr>
    <tr>
      <td>Whether we directly <font color="blue">manufacture</font> products or <font color="blue">contract with</font> another company to     <font color="blue">manufacture</font> products <font color="blue">based on</font> our <font color="blue">technology</font>, the FDA and other <font color="blue">government</font>     <font color="blue">agencies will continually review</font> and <font color="blue">periodically</font> inspect the <font color="blue">manufacturing</font>     process</td>
    </tr>
    <tr>
      <td>If any of these agencies were to discover a <font color="blue">problem with</font> our     products, the <font color="blue">manufacturing</font> process or the <font color="blue">manufacturing</font> <font color="blue">facility</font>, they     could place <font color="blue"><font color="blue">restrictions</font> on</font> these products and on the <font color="blue">manufacture</font>r and     <font color="blue">impose sanctions</font></td>
    </tr>
    <tr>
      <td>For example, the FDA could require us to recall, or even     totally  withdraw,  a <font color="blue">product from</font> the market or close a <font color="blue">manufacturing</font>     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In addition to FDA <font color="blue">regulations</font>, the process of <font color="blue">manufacturing</font> products is     subject to a variety of <font color="blue"><font color="blue">environment</font>al laws</font> and <font color="blue">regulations</font>, including laws     and <font color="blue">regulations</font> governing the use, <font color="blue">management</font> and disposal of <font color="blue">hazardous</font>,     <font color="blue">radioactive</font> and <font color="blue"><font color="blue">infectious</font> materials</font> and wastes, the discharge of <font color="blue">pollutants</font>     into the air and water, and the cleanup of <font color="blue">contaminated sites</font></td>
    </tr>
    <tr>
      <td>We could     incur substantial costs, including cleanup costs, fines and penalties,     claims for damages, such as personal injury or <font color="blue">property damages</font>, and loss of     permits required for our <font color="blue">operations</font>, if we fail to <font color="blue">comply with</font> these laws or     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are also subject to <font color="blue">various employee health</font> and     <font color="blue">safety laws</font> and <font color="blue">regulations</font>, including those <font color="blue">concerning occupational injury</font>     and illness and <font color="blue">employee exposure</font> to <font color="blue">hazardous</font>, <font color="blue">radioactive</font> and <font color="blue">infectious</font>     materials</td>
    </tr>
    <tr>
      <td>While we have procedures in place to <font color="blue">protect employees from exposure</font> to such     materials, we <font color="blue">cannot assure</font> you that <font color="blue">potentially harmful exposure will</font> not     occur or that we will not be liable to <font color="blue">employees as</font> a result</td>
    </tr>
    <tr>
      <td>In addition,     because of the limited information <font color="blue">currently available</font> regarding some of the     <font color="blue">hazardous</font>, <font color="blue">radioactive</font> and <font color="blue"><font color="blue">infectious</font> materials</font> used in our <font color="blue">businesses</font>,     there may be <font color="blue">unknown risks involved with</font> the use of and exposure to such     materials</td>
    </tr>
    <tr>
      <td>In some <font color="blue">circumstances there may</font> be no body of knowledge or     standard protocols for <font color="blue">dealing with</font> these risks</td>
    </tr>
    <tr>
      <td>Costs <font color="blue">associated with</font> such     <font color="blue">environment</font>al, health and <font color="blue">safety matters could</font> have a material adverse     effect on our business and financial       condition</td>
    </tr>
    <tr>
      <td>Our <font color="blue">biosecurity</font> products are subject to stringent Federal, state, local and     foreign laws, <font color="blue">regulations</font> and <font color="blue">policies governing</font> their <font color="blue">manufacture</font>, storage,     sale, <font color="blue">distribution</font> and export</td>
    </tr>
    <tr>
      <td>In addition, the US <font color="blue">government</font> has adopted,     and is expected to continue to adopt, laws, <font color="blue">regulations</font> and <font color="blue">rules governing</font>     the research, <font color="blue">development</font>, procurement and handling of pathogens that may be     used in a <font color="blue">bioterrorist attack</font> or other agents that may cause a <font color="blue">public health</font>     emergency and to permit <font color="blue">government</font> inspection and oversight of <font color="blue">facilities</font>     engaged in the research, <font color="blue">development</font>, <font color="blue">manufacture</font> or sale of select agents</td>
    </tr>
    <tr>
      <td>Under  several  statutes  <font color="blue">recently enacted</font>, the Department of Homeland     Security,  FDA,  Department  of  Commerce and various other <font color="blue">regulatory</font>     <font color="blue">authorities</font> have been charged with <font color="blue">establishing</font> and <font color="blue">implementing</font> programs     designed to enhance the security of food and water supplies, as well as the     <font color="blue">environment</font>, from terrorist attacks</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">legislative</font> <font color="blue">initiatives</font></font> include     recordkeeping, registration, notification, import, export, <font color="blue">manufacturing</font> and     various other <font color="blue">compliance measures</font></td>
    </tr>
    <tr>
      <td>This is a rapidly evolving <font color="blue">regulatory</font>     landscape and many of the <font color="blue">possible rules</font> and <font color="blue">regulations</font> have not yet been     proposed or adopted</td>
    </tr>
    <tr>
      <td>We may be required to incur <font color="blue">significant</font> costs to comply     <font color="blue">with such laws</font> and <font color="blue">regulations</font> in the future, and such laws or <font color="blue">regulations</font>     may have a material adverse effect upon our ability to do business</td>
    </tr>
    <tr>
      <td>In     addition,  the DOD or other <font color="blue">government</font> agencies may require <font color="blue">additional</font>     <font color="blue">security measures</font> to be <font color="blue">implemented at</font> our <font color="blue">facility</font>, <font color="blue">which could</font> cause us to     incur substantial <font color="blue">additional</font> costs</td>
    </tr>
    <tr>
      <td>OUR BUSINESS COULD BE ADVERSELY AFFECTED BY A NEGATIVE AUDIT BY THE US     GOVERNMENT         US  <font color="blue">government</font>  agencies  <font color="blue">routinely audit</font> and investigate <font color="blue">government</font>     <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">agencies review</font> a contractor’s <font color="blue">performance under</font> its     contracts</td>
    </tr>
    <tr>
      <td>If an audit results in a finding of <font color="blue">improper activities</font>, we may     be subject to civil and <font color="blue">criminal penalties</font> and <font color="blue">administrative sanctions</font>,     including <font color="blue">termination</font> of contracts, forfeiture of profits, suspension of     payments, fines and suspension or <font color="blue">prohibition from</font> doing business with the     US <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">could suffer</font> serious harm to our business     reputation if <font color="blue">allegations</font> of <font color="blue">impropriety</font> were made <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>COST OVER-RUNS ON CONTRACTS WITH THE US GOVERNMENT COULD SUBJECT US TO     LOSSES OR ADVERSELY AFFECT OUR FUTURE BUSINESS         Our US <font color="blue"><font color="blue">government</font> contracts</font> are fixed-price contracts and therefore we     receive a fixed <font color="blue">price irrespective</font> of the         37       ______________________________________________________________________         <font color="blue">actual costs</font> we incur in <font color="blue"><font color="blue">connection</font> with</font> the performance of the contracts</td>
    </tr>
    <tr>
      <td>Consequently, we will be required to absorb any costs in excess of the fixed     price that may be set forth in the contract</td>
    </tr>
    <tr>
      <td>If we are unable to control the     costs we incur in performing under these contracts, our <font color="blue">financial condition</font>     and operating results could be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Cost over-runs     also may <font color="blue">adversely</font> affect our ability to sustain our <font color="blue">performance under</font> the     contracts and obtain future US <font color="blue">government</font> contract awards</td>
    </tr>
    <tr>
      <td>RESTRICTIONS ON HEALTHCARE COSTS AND HEALTHCARE AND INSURANCE FINANCING     PRACTICES COULD LIMIT DEMAND FOR OUR PRODUCTS, WHICH WOULD HURT OUR BUSINESS     AND BUSINESS PROSPECTS         In  the  US and elsewhere, demand for clinical <font color="blue">diagnostic</font> testing is     <font color="blue">dependent</font>, in part, on consumers’ ability to be reimbursed for the cost of     the  tests  by third-party payers, such as <font color="blue">government</font> agencies, health     maintenance  <font color="blue">organizations</font>  and  private  insurers</td>
    </tr>
    <tr>
      <td>Medicaid and other     third-party payers are <font color="blue">increasingly challenging</font> the <font color="blue">prices charged</font> for     medical  services,  including clinical <font color="blue">diagnostic</font> tests</td>
    </tr>
    <tr>
      <td>They are also     attempting to <font color="blue">contain costs by limiting</font> their coverage of, and the amount     they <font color="blue">will reimburse</font> for, clinical <font color="blue">diagnostic</font> tests and other healthcare     products</td>
    </tr>
    <tr>
      <td>Without <font color="blue">adequate coverage</font> and reimbursement, consumer demand for clinical     <font color="blue">diagnostic</font> tests may decrease</td>
    </tr>
    <tr>
      <td><font color="blue">Decreased </font><font color="blue">demand would likely</font> cause potential     sales of our clinical <font color="blue">diagnostic</font> products, and sales by our licensees, to     decrease because <font color="blue">fewer tests would</font> be performed or <font color="blue">prices would</font> be lowered,     or  both</td>
    </tr>
    <tr>
      <td>Reduced sales or <font color="blue">royalty income would hurt</font> our business and     business prospects</td>
    </tr>
    <tr>
      <td>In many foreign markets, <font color="blue">government</font>s directly set the prices that clinical     <font color="blue">diagnostic</font> companies may charge for their       products and services</td>
    </tr>
    <tr>
      <td>In the US, a number of <font color="blue">legislative</font> and <font color="blue">regulatory</font>     proposals aimed at changing the healthcare system have been proposed in     recent  years  and  we  expect  this to continue</td>
    </tr>
    <tr>
      <td>Foreign and domestic     <font color="blue">legislative</font> and <font color="blue">regulatory</font> <font color="blue">initiatives</font> that limit healthcare coverage may     have a material adverse effect on our business and business prospects</td>
    </tr>
    <tr>
      <td>Risks Relating to the Industry         WE ARE EXPOSED TO PRODUCT LIABILITY RISKS THAT, IF NOT ADEQUATELY COVERED BY     INSURANCE, MAY HAVE A MATERIAL ADVERSE EFFECT ON OUR FINANCIAL CONDITION         Product <font color="blue">liability</font> is a <font color="blue">major risk</font> in <font color="blue">marketing products</font> for vaccines and for     the clinical <font color="blue"><font color="blue">diagnostic</font>s</font>, <font color="blue">biosecurity</font> and <font color="blue">industrial markets</font></td>
    </tr>
    <tr>
      <td>We may not be     able to <font color="blue">insure ourselves adequately against risk</font> of product <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We     may face product <font color="blue">liability</font> for claims and <font color="blue">lawsuits brought by customers</font></td>
    </tr>
    <tr>
      <td>Damages awarded in product <font color="blue">liability</font> cases can be very large</td>
    </tr>
    <tr>
      <td>While we have     product <font color="blue">liability</font> insurance, this coverage is limited</td>
    </tr>
    <tr>
      <td>We may not have adequate product <font color="blue">liability</font> insurance to <font color="blue">cover us against</font> our     <font color="blue">potential liabilities</font> or be able to maintain <font color="blue">current levels</font> of product     <font color="blue">liability</font> insurance on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>Claims or losses in     excess of our product <font color="blue">liability</font> insurance coverage or not covered by our     product <font color="blue">liability</font> insurance could have a material adverse effect on our     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Common Stock         OUR EXECUTIVE OFFICERS AND DIRECTORS EXERCISE SIGNIFICANT INFLUENCE OVER US     AND MAY HAVE SIGNIFICANT INFLUENCE OVER THE OUTCOME OF PROPOSED CORPORATE     ACTIONS SUPPORTED OR OPPOSED BY OTHER STOCKHOLDERS         Our <font color="blue"><font color="blue">executive officer</font>s</font> and <font color="blue">directors</font>, in the aggregate, own <font color="blue">approximately</font>     24prca of the <font color="blue">outstanding shares</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our chairman and chief     <font color="blue">executive officer</font> owns <font color="blue">approximately</font> 19prca of the <font color="blue">outstanding shares</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a result, certain of our <font color="blue"><font color="blue">executive officer</font>s</font> or <font color="blue">directors</font>     may have <font color="blue">significant</font> influence over the election of <font color="blue">directors</font> and may be     able to <font color="blue">significant</font>ly influence the outcome of proposed corporate actions     supported or <font color="blue">opposed by</font> other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, as a result of     their stockholdings, certain of our <font color="blue"><font color="blue">executive officer</font>s</font> and <font color="blue">directors</font> could     have <font color="blue">significant</font> influence over the outcome of potential <font color="blue">transactions</font>,     including any <font color="blue">acquisition</font> <font color="blue">transactions</font>, that may be supported or <font color="blue">opposed by</font>     other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>38       ______________________________________________________________________           PROVISIONS IN OUR CHARTER DOCUMENTS MAY DISCOURAGE POTENTIAL ACQUISITIONS OF     US, EVEN THOSE WHICH THE HOLDERS OF A MAJORITY OF OUR COMMON STOCK MAY     FAVOR, WHICH MAY ADVERSELY AFFECT THE MARKET PRICE OF OUR COMMON STOCK,     REDUCE THE LIKELIHOOD OF OFFERS TO ACQUIRE US AND PREVENT CHANGES IN OUR     MANAGEMENT         Our <font color="blue">certificate</font> of <font color="blue">in<font color="blue">corporation</font></font> and by-laws contain provisions that may     have the effect of <font color="blue">discouraging</font> a <font color="blue">third party</font> from acquiring us by means of     a <font color="blue">tender offer</font>, proxy contest or otherwise</td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">in<font color="blue">corporation</font></font>     and by-laws:         •       classify our board of <font color="blue">directors</font> into three classes, with <font color="blue">directors</font> of each     class serving for a staggered three-year period;         •       provide that our <font color="blue">directors</font> may be <font color="blue">removed only</font> for cause and only upon the     approval of the holders of at least a majority of the <font color="blue">voting power</font> of all     our <font color="blue">shares entitled</font> to <font color="blue">vote generally</font> in the election of such <font color="blue">directors</font> then     outstanding, voting together as a single class;         •       prohibit our <font color="blue">stockholders</font> from calling special meetings and <font color="blue">prohibit action</font>     by our <font color="blue">stockholders</font> by written consent;         •       require at least 66 2/3prca of the <font color="blue">voting power</font> of all our <font color="blue">shares entitled</font> to     <font color="blue">vote generally</font> in the election of <font color="blue">directors</font> then       outstanding, voting together as a single class, to alter, amend or repeal     <font color="blue">certain provisions</font>, including the provisions relating to our classified     board, the election, appointment and removal of our <font color="blue">directors</font> and <font color="blue">action by</font>     <font color="blue">stockholders</font> by written consent described above;         •       permit our board of <font color="blue">directors</font> to <font color="blue">fill vacancies</font> and newly created     <font color="blue">directors</font>hips on our board of <font color="blue">directors</font>; and         •       <font color="blue">contain advance</font> notice <font color="blue">requirements</font> for <font color="blue">stockholder proposals</font></td>
    </tr>
    <tr>
      <td>In addition, under our <font color="blue">certificate</font> of <font color="blue">in<font color="blue">corporation</font></font>, our board of <font color="blue">directors</font>     also has the authority to issue up to 15cmam000cmam000 shares of <font color="blue">preferred stock</font>     in  one  or  more  series</td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> can fix the powers,     <font color="blue">preferences</font> and rights of any <font color="blue">such series without stockholder approval</font></td>
    </tr>
    <tr>
      <td>Our     board of <font color="blue">directors</font> could, therefore, issue, without stockholder approval,     <font color="blue">preferred stock</font> with voting and other rights that could <font color="blue">adversely</font> affect the     <font color="blue">voting power</font> of the holders of our <font color="blue">common stock</font> or otherwise make it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to <font color="blue">gain control</font> of us</td>
    </tr>
    <tr>
      <td>Such <font color="blue">provisions would</font>     make the removal of incumbent <font color="blue">directors</font> more <font color="blue">difficult</font> and time-consuming     and may have the effect of <font color="blue">discouraging</font> a <font color="blue">tender offer</font> or other takeover     attempt not <font color="blue">previously approved by</font> our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>In addition, we have adopted a stockholder rights <font color="blue">agreement</font>, pursuant to     which one right attached to each share of our <font color="blue">common stock</font> outstanding</td>
    </tr>
    <tr>
      <td>These rights will in most cases cause substantial dilution to a person that     attempts to acquire or <font color="blue">merge with us</font> without the approval of our board of     <font color="blue">directors</font> by permitting the holders of these rights (other than the person     attempting to acquire or <font color="blue">merge with us</font>) to, upon the occurrence of specified     circumstances, purchase, at a substantial discount, shares of our <font color="blue">Series A     </font>participating cumulative <font color="blue">preferred stock</font> or shares of <font color="blue">common stock</font> of the     person that attempts to acquire or <font color="blue">merge with us</font></td>
    </tr>
    <tr>
      <td>Accordingly, the existence     of  these  rights may deter potential <font color="blue">acquirers</font> from making a takeover     proposal or a <font color="blue">tender offer</font></td>
    </tr>
    <tr>
      <td>WE DO NOT PLAN TO PAY ANY CASH DIVIDENDS ON OUR COMMON STOCK         We  have  no  plans  to  <font color="blue">pay cash dividends on</font> our <font color="blue">common stock</font> in the     <font color="blue">foreseeable future</font>, if at all</td>
    </tr>
    <tr>
      <td>WE MAY NEED TO RAISE ADDITIONAL CAPITAL IN THE FUTURE AND WE MAY GRANT     OPTIONS OR OTHER EQUITY-BASED AWARDS TO OUR EXECUTIVE OFFICERS, DIRECTORS,     EMPLOYEES AND CONSULTANTS, FROM TIME TO TIME, EITHER OF WHICH WOULD RESULT     IN DILUTION TO OUR STOCKHOLDERS         Your <font color="blue">investment</font> in our <font color="blue">common stock</font> could be diluted if we issue <font color="blue">additional</font>     shares of our <font color="blue">common stock</font> or <font color="blue">securities convertible into</font>, or exercisable     for, shares of our <font color="blue">common stock</font> in the future, which we may need to do to     <font color="blue">raise funds</font>         39       ______________________________________________________________________         for our business</td>
    </tr>
    <tr>
      <td>Sales of <font color="blue">additional</font> shares of our <font color="blue">common stock</font> or the     <font color="blue">conversion</font> of securities into, or the exercise of securities for, shares of     our  common  <font color="blue">stock could</font> cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to     decrease</td>
    </tr>
    <tr>
      <td>Under  the BioVeris 2003 stock incentive plan, our <font color="blue"><font color="blue">executive officer</font>s</font>,     <font color="blue">directors</font>, employees and <font color="blue">consultants</font> are from time to time <font color="blue">granted options</font>     or other equity-based awards, such as phantom stock or <font color="blue">restricted stock</font>, to     <font color="blue">purchase up</font> to 5dtta3 million shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If our executive     officers, <font color="blue">directors</font>, employees and <font color="blue">consultants</font> exercise their options or     other equity-based awards, if and when granted and exercisable, and purchase     shares of our <font color="blue">common stock</font>, your <font color="blue">investment</font> in our <font color="blue">common stock</font> will be     diluted</td>
    </tr>
    <tr>
      <td>THE  EXON-FLORIO ACT MAY INHIBIT POTENTIAL ACQUISITION BIDS, WHICH MAY     ADVERSELY AFFECT THE MARKET PRICE OF OUR COMMON STOCK         Section 721 of <font color="blue">Title VII of the Defense Production Act </font>of 1950, also known     as  the  Exon-Florio  Act, <font color="blue">authorizes</font> the <font color="blue">President of the US </font>or his     designees  to  initiate an <font color="blue">investigation</font> into the potential effects on     national security of a business <font color="blue">combination</font> of a US <font color="blue">corporation</font> and a     foreign entity that could result in <font color="blue">foreign control</font> of the US <font color="blue">corporation</font></td>
    </tr>
    <tr>
      <td>Subject to certain <font color="blue">exceptions</font>, under the Exon-Florio Act, the president may     suspend or prohibit any foreign <font color="blue">acquisition</font>, merger or takeover of a US     <font color="blue">corporation</font> if there is <font color="blue">credible evidence</font> that the foreign entity exercising     <font color="blue">control might</font> take action that <font color="blue">threatens national security</font> and there is no     provision of <font color="blue">law adequate</font> to <font color="blue">protect national security</font></td>
    </tr>
    <tr>
      <td>Due to our current     and potential future involvement in the <font color="blue">biodefense industry</font>, the Exon-Florio     Act could inhibit potential <font color="blue">acquisition</font> bids from foreign entities, which     could <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>